Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

DualityBio to IPO on Hong Kong Exchange

publication date: Aug 26, 2024

Shanghai DualityBio plans to conduct a Hong Kong IPO to support its portfolio of ADC therapeutics for cancer and autoimmune diseases. Founded in 2019, DualityBio has built an innovative and differentiated pipeline of 12 ADC candidates, discovered in-house. These include six clinical-stage ADCs aimed at indications with unmet medical needs, two next-generation bispecific ADCs (BsADCs) and one autoimmune ADC planned for clinical trials over the next two years. The company has forged partnerships with BioNTech SE, BeiGene, Ltd. and Adcendo ApS with a total deal value of more than $4.0 billion. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here